NO20031673L - Behandling av kreft - Google Patents

Behandling av kreft

Info

Publication number
NO20031673L
NO20031673L NO20031673A NO20031673A NO20031673L NO 20031673 L NO20031673 L NO 20031673L NO 20031673 A NO20031673 A NO 20031673A NO 20031673 A NO20031673 A NO 20031673A NO 20031673 L NO20031673 L NO 20031673L
Authority
NO
Norway
Prior art keywords
cancer
treatment
aplidine
carnitine
useful
Prior art date
Application number
NO20031673A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031673D0 (no
Inventor
Lazaro Luis Lopez
Jose Maria Fernandez-Sousa
Jean-Pierre Armand
Eric Raymond
Original Assignee
Ruffles Graham Keith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025044A external-priority patent/GB0025044D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Priority claimed from PCT/GB2000/004349 external-priority patent/WO2001035974A2/en
Priority claimed from GB0107373A external-priority patent/GB0107373D0/en
Priority claimed from PCT/GB2001/004555 external-priority patent/WO2002030441A2/en
Application filed by Ruffles Graham Keith filed Critical Ruffles Graham Keith
Publication of NO20031673D0 publication Critical patent/NO20031673D0/no
Publication of NO20031673L publication Critical patent/NO20031673L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NO20031673A 2000-10-12 2003-04-11 Behandling av kreft NO20031673L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0025044A GB0025044D0 (en) 2000-10-12 2000-10-12 Toxicity protection
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers
GB0107373A GB0107373D0 (en) 2001-03-23 2001-03-23 Aplidine
PCT/GB2001/004555 WO2002030441A2 (en) 2000-10-12 2001-10-12 Treatment of cancers by aplidine in conjunction with a myoprotector

Publications (2)

Publication Number Publication Date
NO20031673D0 NO20031673D0 (no) 2003-04-11
NO20031673L true NO20031673L (no) 2003-06-12

Family

ID=27255931

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031673A NO20031673L (no) 2000-10-12 2003-04-11 Behandling av kreft

Country Status (14)

Country Link
US (1) US7507766B2 (cs)
JP (1) JP2010031043A (cs)
KR (1) KR20030038812A (cs)
CN (1) CN1479622A (cs)
AT (1) ATE299028T1 (cs)
BR (1) BR0114604A (cs)
CZ (1) CZ2003993A3 (cs)
ES (1) ES2243555T3 (cs)
HK (1) HK1054191A1 (cs)
IL (1) IL155273A0 (cs)
NO (1) NO20031673L (cs)
NZ (1) NZ525196A (cs)
PL (1) PL361179A1 (cs)
RU (1) RU2003113210A (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302498B6 (cs) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
CN100409895C (zh) * 2003-03-12 2008-08-13 法马马有限公司 用于治疗白血病和淋巴瘤的阿普立定组合
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
EP2029155B1 (en) * 2006-02-28 2016-04-13 Pharma Mar S.A. Improved treatment of multiple myeloma
JP2011500650A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
RU2010140888A (ru) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные противораковые терапии
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
EP0048149B1 (en) 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
CA2255615C (en) 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
ES2135360T3 (es) 1996-07-03 2002-05-16 Paxton C G Ltd Recipiente.
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
DE69840497D1 (de) 1997-05-07 2009-03-12 William J Crumb Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU764807B2 (en) * 1998-07-30 2003-08-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU781897B2 (en) 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
CZ302498B6 (cs) 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA03002479A (es) 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
CA2424823A1 (en) 2000-10-12 2002-04-18 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
AU2002336206B2 (en) 2001-10-19 2007-11-29 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
CN100409895C (zh) 2003-03-12 2008-08-13 法马马有限公司 用于治疗白血病和淋巴瘤的阿普立定组合

Also Published As

Publication number Publication date
ATE299028T1 (de) 2005-07-15
NZ525196A (en) 2004-09-24
BR0114604A (pt) 2003-10-14
CZ2003993A3 (cs) 2004-02-18
ES2243555T3 (es) 2005-12-01
HK1054191A1 (zh) 2003-11-21
JP2010031043A (ja) 2010-02-12
KR20030038812A (ko) 2003-05-16
US7507766B2 (en) 2009-03-24
US20040010043A1 (en) 2004-01-15
NO20031673D0 (no) 2003-04-11
PL361179A1 (en) 2004-09-20
CN1479622A (zh) 2004-03-03
IL155273A0 (en) 2003-11-23
RU2003113210A (ru) 2004-11-27

Similar Documents

Publication Publication Date Title
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
EA200501251A1 (ru) Антинеопластические комбинации
HN2001000243A (es) Inhibidores de metaloproteinasa del tipo pirimidin - 2, 4, 6 - triona
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
EP1240280A4 (en) PROCESS FOR TREATING COAL
PT1235571E (pt) Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
NO994274L (no) Sammensetninger til Õ behandle tumörer inneholdende haibruskekstrakter og antineoplastiske forbindelser
SE9802208D0 (sv) Novel compounds
NO20031860L (no) Kahalalid F
DK1294372T3 (da) Törpulverformulering der omdanner racecadotril
NO20031673D0 (no) Behandling av kreft
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ATE275143T1 (de) Verbindungen
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
SE9802209D0 (sv) Novel compounds
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DE60103685D1 (de) Behandlung von Poriomania

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application